Price reduction for Ezetrol tablets

An announcement published in the Journal officiel on Wednesday, October 14, sets new prices for ezetimibe 10 mg, following agreements between the Economic Committee for Health Products (CEPS), BB Farma, and Organon France.

Medical use and insurance coverage

Approved in France since 2010, Ezetrol is indicated for primary hypercholesterolemia, prevention of cardiovascular events, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. It is covered by the Health Insurance at 65 percent.

New public prices for different package sizes

The public price including tax of Ezetrol 10 mg will be set at 10.90 euros for 28 tablets (CIP: 34009 362 270 7 1) and 33.08 euros for 90 tablets (CIP: 34009 391 700 6 0), representing a decrease of approximately 9 percent. Generic versions of ezetimibe are also affected by this price revision, including Accord, Almus, Alter, Arrow, Biogaran, Cristers, EG Labo, Evolupharm, Krka, Sandoz, Teva, Viatris, Zentiva, and Zydus.

Timing and acquisition context

This decrease occurs while Organon is undergoing acquisition by Sun Pharma. For pharmacies, the new price must be applied starting January 2, 2027. No information has been provided regarding a possible price decrease for specialty products combining ezetimibe with another molecule, such as in Liptruzet (ezetimibe/atorvastatin).